SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis

Lambert H, Gupte J, Fletcher H, Hammond L, Lowe N, Pelling M et al (2020) COVID-19 as a global challenge: towards an inclusive and sustainable future. Lancet Planet Health 4(8):e312-314

Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, Pinior B, Thurner S, Klimek P (2020) Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav 4(12):1303–1312

Gasparyan AY, Misra DP, Yessirkepov M, Zimba O (2020) Perspectives of immune therapy in Coronavirus disease 2019. J Korean Med Sci 35(18):e176

Georgiev T, Angelov AK (2020) Complexities of diagnosis and management of COVID-19 in autoimmune diseases: potential benefits and detriments of immunosuppression. World J Clin Cases 8(17):3669–3678

Fontanet A, Cauchemez S (2020) COVID-19 herd immunity: where are we? Nat Rev Immunol 20(10):583–584

Saxena S, Skirrow H, Bedford H (2020) Routine vaccination during covid-19 pandemic response. BMJ 369:m2392

Burgess RA, Osborne RH, Yongabi KA, Greenhalgh T, Gurdasani D, Kang G et al (2020) The COVID-19 vaccines rush: participatory community engagement matters more than ever. Lancet S0140673620326428

Global Alliance for Vaccines and Immunizations (GAVI) (2020) The latest in the COVID-19 vaccine race. Available from: https://www.gavi.org/vaccineswork/covid-19-vaccine-race. Accessed 14 Dec 2020

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417

Theofilopoulos AN, Kono DH, Baccala R (2017) The multiple pathways to autoimmunity. Nat Immunol 18(7):716–724

Galeotti C, Bayry J (2020) Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 16(8):413–414

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists’ perspective on Coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39(7):2055–2062

European League Against Rheumatism (EULAR) (2020) EULAR—COVID-19 Database. Available from https://www.eular.org/eular_covid19_database.cfm. Accessed 19 Dec 2020

Kłodziński Ł, Wisłowska M (2018) Comorbidities in rheumatic arthritis. Reumatologia 56(4):228–233

Kipps S, Paul A, Vasireddy S (2020) Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic? Clin Rheumatol 11:1–5

Serling-Boyd N, D'Silva KM, Hsu TY, Wallwork R, Fu X, Gravallese EM et al (2020) Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis

Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S et al (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202(2):149–161

Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39–52

Ahmed S, Gasparyan AY, Zimba O (2021) Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 41:243–256

Munz C, Lunemann JD, Getts MT, Miller SD (2009) Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 9:246–258

Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5:648–652

Schattner A (2005) Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23:3876–3886

Salemi S, D’Amelio R (2010) Could autoimmunity be induced by vaccination? Int Rev Immunol 29:47–69

Vadalà M, Poddighe D, Laurino C, Palmieri B (2017) Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J 8(3):295–311

De Martino M, Chiappini E, Galli L (2013) Vaccines and autoimmunity. Int J Immunopathol Pharmacol 26(2):283–290

Rodríguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, Monsalve DM et al (2018) Guillain–Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol 15(6):547–562

Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R (2005) High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol 169(1–2):31–38

Sioofy-Khojine AB, Lehtonen J, Nurminen N, Laitinen OH, Oikarinen S, Huhtala H et al (2018) Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia 61(5):1193–1202

Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K et al (1998) Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 95(14):8227–8232

Institute of Medicine (2011) Adverse effects of vaccines: evidence and causality. The National Academies Press, Washington DC

Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity-friends or foes? Trends Immunol 30:409–414

Rioux JD, Abbas AK (2005) The genetics of complex autoimmune diseases. Nature 435:584–589

Chen RT, Pless R, De Stefano F (2001) Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 16(3):309–318

Szwejkowska M, Kuchar E (2020) Vaccinations in rheumatic diseases. Reumatologia 58(2):61–62

Colmegna I, Useche ML, Rodriguez K, McCormack D, Alfonso G, Patel A et al (2019) Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-compatator trial. Lancet Rheum 2(1):E14–E23

Flanagan KL, Fink AL, Plebanski M, Klein SL (2017) Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol 33:577–599

Dhakal S, Klein SL (2019) Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs. J Virol 93(21):e00797-e819

Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB et al (2012) Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes 36:1072–1077

Campos LM, Silva CA, Aikawa NE, Jesus AA, Moraes JC, Miraglia J et al (2013) High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65(7):1121–1127

World Health Organization (2020) Draft landscape of COVID-19 candidate vaccines. Available from https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 18 Dec 2020

Lurie N, Saville M, Hatchett R, Halton J (2020) Developing COVID-19 vaccines at pandemic speed. N Engl J Med 382(21):1969–1973

Le Thanh T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (2020) The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19(5):305–306

Chang CC, Chang YS, Chen WS, Chen YH, Chen JH (2016) Effects of annual influenza vaccination on morbidity and mortality in patients with systemic lupus erythematosus: a nationwide cohort study. Sci Rep 6:37817

Kostianovsky A, Charles P, Alves JF, Goulet M, Pagnoux C, Le Guern V et al (2012) French Vasculitis Study Group. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 30:S83–S89

Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I et al (2008) Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 67(7):937–941

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087–2096

Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J et al (2020) Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk/benefit assessment. Vaccine

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al (2020) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111

De Haan P, Van Diemen FR, Toscano MG (2020) Viral gene delivery vectors: the next generation medicines for immune-related diseases. Hum Vaccin Immunother 15:1–8

Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov 17(4):261–279

Weissman D (2015) mRNA transcript therapy. Expert Rev Vaccines 14:265–281

Sahin U, Kariko K, Tureci O (2014) mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov 13:759–780

Rauch S, Jasny E, Schmidt KE, Petsch B (2018) New vaccine technologies to combat outbreak situations. Front Immunol 9:1963

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615

Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833–1840

Kauffman KJ, Webber MJ, Anderson DG (2016) Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release 240:227–234

Guan S, Rosenecker J (2017) Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther 24:133–143

Thess A, Grund S, Mui BL, Hope MJ, Baumhof P, Fotin-Mleczek M, Schlake T (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23(9):1456–1464

Kariko K, Muramatsu H, Ludwig J, Weissman D (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39:e142

Isaacs A, Cox RA, Rotem Z (1963) Foreign nucleic acids as the stimulus to make interferon. Lancet 2:113–116

Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T et al (2017) Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med 15(1):1

Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z (2020) Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 20(10):615–632

US Food and Drug Administration (FDA) (2020) Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document Moderna COVID-19 Vaccine. Available from https://www.fda.gov/media/144434/download. Accessed 20 Dec 2020